Cyprotex PLC (Cyprotex) is a holding company specializing in preclinical ADME Tox, both in vitro (laboratory experiments) and in silico (computer modelling). The principal activities of the Company, along with its subsidiaries, are that of providing in vitro and in silico Absorption, Distribution, Metabolism, Excretion, Toxicity and Pharmacokinetics (ADMET and PK) information to the pharmaceutical and biotechnology industries. The Company�s in vitro ADME and DMPK services include in vitro metabolism, in vitro permeability and transporters, solubility and physicochemical properties, in vitro protein binding and PK and bioanalysis. Cyprotex serves drug-discovery organizations, which include pharmaceutical companies, small virtual companies, as well as academic and not-for-profit laboratories. It also supports the research efforts of the cosmetic and agrochemical industries, principally for in vitro toxicity testing. Its subsidiaries are Cyprotex Discovery Limited and Apredica, LLC.